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Abstract. Growth-hormone (GH) secreting adenomas, in-
cluding acromegaly, account for approximately one-sixth of
all pituitary adenomas and are associated with mortality
rates at least twice that of the general population. The ul-
timate goal of therapy for acromegaly is normalization of
morbidity and mortality rates achieved through removal or
reduction of the tumor mass and normalization of insulin-
like growth factor I (IGF-I) levels. Previously published
efficacy results of current treatment modalities (surgery,
conventional radiation, and medical therapy with dopamine
agonists and somatostatin analogs) are often difficult to
compare because of the different criteria used to define cure
(some of which are now considered inadequate). For each
of these modalities, pooled data from a series of acromegaly
studies were reviewed for rates of IGF-I normalization, a
currently accepted definition of cure. The results showed
overall cure rates of approximately 10% for bromocrip-
tine, 34% for cabergoline, 36% for conventional radiation,
50–90% for surgery for microadenomas and less than 50%
for macroadenomas, and 54–66% for octreotide. These cure
rates based on IGF-I normalization are generally less than
those reported for cure based solely on GH levels. Novel new
therapies for acromegaly include the somatostatin analog,
lanreotide, Gamma Knife radiosurgery, and pegvisomant,
the first in its class of new GH receptor antagonists. Al-
though it does not appear that Gamma Knife radiosurgery
results in significantly higher cure rates or fewer compli-
cations, it does provide a notable improvement in delivery
compared with conventional radiation. Early studies have
reported IGF-I normalization in 48% of lanreotide-treated
patients and up to 97% of pegvisomant-treated.
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I. Incidence and Prevalence
of Pituitary Tumors
Occult pituitary adenomas are common and have been
observed in 10% of normal volunteers studied by mag-
netic resonance imaging (MRI) of the pituitary gland
[1]. Most pituitary adenomas remain asymptomatic
and do not require treatment, and clinically signifi-
cant tumors are relatively rare. In a Canadian epi-
demiological study, the overall incidence rates for
intracranial neoplasms have been estimated to be
10.2 and 10.8 per 100,000 for men and women, re-
spectively [2]. Community and hospital-based stud-
ies have shown pituitary adenomas to be the third
most common primary intracranial tumor following
astrocytoma and meningioma [2–4]. The incidence
of pituitary adenoma in Sweden, excluding growth
hormone (GH)-secreting adenomas (acromegaly) and
adrenocorticotrophic-hormone (ACTH)-secreting ade-
nomas (Cushing’s disease), rose from approximately
5–10/million/year in the 1950s and 1960s to approxi-
mately 10–15/million/year in the 1990s. This increase in
incidence was observed for both men and women and
was probably due to better diagnostic skills and aware-
ness. More recently, a population study in the UK esti-
mated the overall incidence of pituitary adenomas to be
2.5/100,000/year [4].
A retrospective review of 2,230 patients who under-
went surgery for a pituitary adenoma between 1969 and
1993 showed prolactinomas to be the most common
type of adenoma (39%), followed by non-functioning
adenomas (27%), GH-secreting adenomas (16%), and
Cushing’s (15%) [5]. ACTH-secreting adenomas caus-
ing Nelson’s syndrome and thyrotropin (TSH)-releasing
adenomas are rare (<3%) [5]. Population-based studies
in the UK, Sweden, Ireland, and Spain estimated the in-
cidence of acromegaly to be 3–6 new cases/million/year
(prevalence of 38–69/million) [3,4,6–8] (Table 1).
The frequency of pituitary adenomas varies greatly
according to age and sex. Overall, more men than
women are diagnosed with pituitary adenomas and have
a peak incidence between 55 and 65 years of age [9]. A
non-functioning adenoma and acromegaly occur equally
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Table 1. Incidence and prevalence of acromegaly
Number of cases Incidence per million Prevalence per million Percent (%) male
Alexander et al., 1980 164 2.8 38 –
Bengtsson et al., 1988 166 3.3 69 46
Ritchie et al., 1990 131 4 63 –
Etxabe et al., 1993 74 3.1 60 35
in men and women and have peak incidences in the older
age groups (fourth to eighth decades), whereas prolacti-
noma and Cushing’s occur more frequently in women
and have peak incidences between the second and fifth
decades of life [5,10]. The greatest discrepancy of gen-
der distribution occurs at the time of peak incidence for
each tumor type [5]. When distributed by tumor size,
men are significantly more likely than women to have
a macroadenoma (tumor size >10 mm) [11]. Overall,
macroadenomas occur more frequently in acromegaly,
as well as for non-functioning adenomas, whereas mi-
croadenomas are more common for prolactinomas and
Cushing’s.
Pituitary tumors are associated with decreased life
expectancy [9]. The mortality rate associated with
acromegaly has been estimated to be at least twice that
in the general population, most commonly from car-
diovascular, pulmonary, and neoplastic disease [3,6,12–
14]. Patients suffering from a macroadenoma are more
likely to have pituitary deficiency; therefore, the prob-
able cause of increased mortality is the impairment of
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Fig. 1. Linear regression analysis of the correlation between fasting IGF-I concentration or growth hormone concentration after
glucose and heel pad thickness, blood glucose one hour after the oral administration of glucose (OGTT), and fasting blood glucose.
Figure modified from D.R. Clemmons et al. NEJM 1979;301:1138–1142. Used with permission.
II. Current Management of Patients
with Acromegaly
The morbidity and mortality of acromegaly are de-
termined by the GH/insulin-like growth factor (IGF-
I)-induced somatic impairments (e.g., cardiac hy-
pertrophy, sleep apnea, arthropathy, risk of cancer
development), mass effects of the tumor, and by the ac-
companying hypopituitarism. Whereas tumor mass ef-
fects and hypopituitarism can be treated with combined
medical and surgical approaches, hormone hypersecre-
tion is often of greatest difficulty to control. The pre-
viously employed cure criteria used to evaluate treat-
ment for acromegaly, spontaneous GH < 2.5 µg/L and
glucose-suppressed GH < 2 µg/L, have been recently
thought to be inadequate [15–17]. Currently, biochemi-
cal cure is defined as serum GH concentrations <1 µg/L
after oral glucose ingestion (using a chemiluminescent
or immunoradiometric assay for GH) and, more impor-
tantly, the reduction of circulating IGF-I levels to nor-
mal (adjusted for age and sex) [15–17] (Fig. 1). Be-
cause of the changes in criteria used for defining cure
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Table 2. Efficacy of therapeutic modalities in the treatment of acromegaly
Percent of patients with
normalized IGF-I∗ Adverse events Comments References
Surgery 67% overall Immediate effect [18–27]
78% microadenomas;
57% macroadenomas
Conventional radiation 36% Hypopituitarism, visual disturbances, Slow response [30–41]
neurological damage and necrosis, Serious complications
secondary brain tumors
Dopamine agonists
Bromocriptine 10% Nausea, constipation, vomiting, Convenient [45–81]
indigestion, dyspepsia, orthostatic Frequent though generally
hypertension, anorexia, dry mouth, mild to moderate side effects
nasal stuffiness, digital vasospasm,
and drowsiness
Cabergoline 34% Nausea, constipation, vomiting, Convenient [82–88]
indigestion, dyspepsia, orthostatic Less frequent gastrointestinal
hypertension, anorexia, dry mouth, side effects than with
nasal stuffiness, digital vasospasm, bromocriptine
and drowsiness
Somatostatin analogs
Octreotide sc 54% Nausea, abdominal pain, diarrhea, Frequent daily self-administered [55,90–123]
gallstones and/or biliary sludge injections
Octreotide LAR 66% Nausea, abdominal pain, diarrhea, Deep intragluteal injections [124–132]
gallstones and/or biliary sludge at 1–6 week intervals
∗Percentages are based on the total number of patients with available IGF-I data as taken from the cited references.
or control of acromegaly, the efficacy results of previ-
ously reported treatment are often difficult to compare.
Current treatment modalities used in the management
of acromegaly (surgery, radiotherapy, and medical ther-
apy with dopamine agonists and somatostatin analogs)
are discussed below with a focus on using the criteria of
IGF-I normalization as the standard of cure or adequate
control (Table 2).
II.A. Surgery
Transsphenoidal surgery for the removal of pituitary
tumors remains the cornerstone of acromegaly ther-
apy. When surgery is performed by an experienced
surgeon, mortality rates are less than 1%, and 80–90%
of microadenomas and up to 50% of macroadenomas
may be completely removed [18–20]. In several recently
reported studies (1995–2001), the surgical outcomes
of 818 patients who had undergone transsphenoidal
surgery for pituitary adenoma were reviewed based on
recent criteria for biochemical cure (normalized IGF-
I, random GH < 2.5 µg/L, and glucose-suppressed GH <
1–2 µg/L) [18–27]. In these studies, the majority of pa-
tients were followed for 1–5 years post surgery (mean
range, 3 months to 16 years). Transsphenoidal surgery
resulted in normalized IGF-I levels in 67% of patients,
random GH < 2.5 µg/L in 58% of patients, and normal
glucose-suppressed GH levels in 66%. Simultaneous nor-
malization of GH and IGF-I were reported in 72% of pa-
tients at follow-up. Patients with microadenomas had
the highest rate of IGF-I normalization of 78%, while,
as expected, patients with macroadenomas fared sig-
nificantly worse—they achieved biochemical cure in
only 57% of cases [19,20,22–24, 26]. One study reported
normalized IGF-I levels in only 20% of patients with
macroadenomas greater than 20 mm in size [23]. Pa-
tients with noninvasive tumors had an overall cure rate
of 85% compared to only 37% of patients with invasive
tumors. Long-term (mean follow-up of >5 years) recur-
rence rates ranged from 0 to 19% [19,21,24–26]. Surgical
experience is yet another important determinant of the
outcome. In one retrospective review [20], an improve-
ment in surgical cure rates by a single surgeon was ob-
served over time, from 45% following surgery performed
prior to 1987 to 73% between 1991 and 1996. Serious sur-
gical complications occur in approximately 1.5% of pa-
tients and mortality is rare (<1%) [25]. For most patients,
surgical management of acromegaly safely provides an
immediate and effective treatment, and may be defini-
tive therapy in some patients. However, differences in
tumor size and invasiveness, as well as in surgical ex-
pertise, dramatically affect surgical outcome. A signif-
icant proportion of patients with acromegaly require
medical therapy or radiation for biochemical control of
acromegaly.
II.B. Conventional radiation
Conventional radiation has been employed as a treat-
ment in patients with acromegaly for many years. Cur-
rently, conventional radiotherapy of a pituitary tumor is
generally delivered in fractionated doses of 160–180 cGy
4–5 times/week over a 5–6 week period so as to admin-
ister 45–50 Gy (4500–5000 rads) [28]. Multiple studies
of radiation have reported declines in GH levels for up
to 20–25 years, with an ultimate cure rate of between
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70–90% (cure defined as GH < 5 µg/L) [29]. A review of
existing data, however, using current criteria for the
cure of acromegaly, has demonstrated that radiation
therapy is much less effective than previously thought.
Radiation has been associated with the reduction of tu-
mor size, and has been shown to normalize serum IGF-I
levels in only about one-third of all patients.
In a series of 12 studies conducted between 1988 and
2001, and including a personal communication from Dr.
Phillippe Jaquet from Marseille, France, 560 patients
with acromegaly were treated with radiotherapy and
followed for an average of 4 to 13 years [30–41]. The
overall frequency of normalization of IGF-I in these pa-
tients was 36%. Patients with a mean or median follow-
up of no more than 7 years had a efficacy rate of 29%
compared to 45% in patients followed longer than 10
years. However, because of an increasing number of
patients lost to follow-up over time, and the greater
likelihood that “lost” patients died prematurely, this
long-term rate of efficacy is most likely inflated. Side
effects related to conventional radiation commonly in-
clude radiation-induced hypopituitarism (up to 50–60%
of patients), and rarely, damage to the optic pathways,
neurological damage and complications, and secondary
brain tumors [29,42]. In addition, because of the slow
biochemical response to radiation, the morbidities of
acromegaly persist for several years following treatment
unless adjunctive medical therapy is successfully used
[29]. As radiation technology improves, the risks of optic
and neurological damage may be further minimized, but
whether there exists causal factors other than radiation
predisposing these patients to secondary brain tumors
has yet to be determined [43,44].
II.C. Dopamine agonists (bromocriptine
and cabergoline)
Dopamine agonists suppress GH release through neg-
ative coupling of dopamine receptors with adenylate
cyclase resulting in direct suppression of GH release
[45]. Dopamine agonists are advantageous in that they
have the convenience of an oral route of administra-
tion; however, published data have shown only limited
effectiveness in the treatment of acromegaly. Of the nu-
merous dopamine agonists developed and used in the
management of patients with acromegaly, bromocrip-
tine is the most widely investigated and has been used
since the early 1970s. Bromocriptine is generally admin-
istered orally several times daily for a total dose ranging
between 7.5 and 80 mg/day. Few patients have exhibited
any benefit at dose levels greater than 20–30 mg/day and
side effects at higher doses can be significant [46–48].
In a review of 34 studies between 1975 and 1990,
616 patients received bromocriptine (7.5–80 mg/day).
Approximately 21% of these patients achieved plasma
GH < 5 µg/mL, but only 10% of achieved normalization
of IGF-I levels [46–79]. Treatment with bromocriptine
has been generally found to be ineffective with regard
to tumor shrinkage, with an incidence of only between
10% and 20% [45]. Frequent side effects include gas-
trointestinal disorders (nausea, constipation, vomiting,
indigestion, and dyspepsia), orthostatic hypertension,
anorexia, dry mouth, nasal stuffiness, digital vasospasm,
and drowsiness [80]. Most symptoms resolve with con-
tinued use of the drug; however, side effects continue in
a significant number of patients [81].
Compared to bromocriptine, a newer orally admin-
istered dopamine agonist, cabergoline, has a more spe-
cific D2 receptor-binding activity and a prolonged dura-
tion of action. Effective dose levels of cabergoline for
the treatment of acromegaly range between 1 mg ad-
ministered twice weekly and 0.5 mg administered daily
(total weekly dose range of 2–3.5 mg). Doses higher than
3.5 mg/week have not been shown to improve efficacy,
but rather, result in decreased tolerability [82]. Caber-
goline, however, has been mainly used in the treatment
of hyperprolactinemic disorders, and its use in the treat-
ment of acromegaly has been studied significantly less
extensively than has bromocriptine. In a series of six
studies conducted between 1988 and 1998, 112 patients
received cabergoline 0.3–7.0 mg/week [82–87]. Normal
IGF-I was achieved in a total of 34% of patients. Although
it appears that cabergoline may be more effective than
bromocriptine, it must be noted that, in addition to the
limited data currently available, the range of efficacy in
these studies varied between 0% and 100%. Side effects
have been reported less frequently during treatment
with cabergoline than with bromocriptine [88].
II.D. Somatostatin analogs (immediate- and
slow-release octreotide)
The natural hormone somatostatin exerts numerous
physiological effects including suppression of GH,
glucagon, and insulin [89]. Somatostatin analogs, far
more potent and longer-acting than natural somato-
statin, are used in the treatment of acromegaly and have
been shown to have a suppressive effect on both hor-
mone hypersecretion and, in some cases, tumor size. Oc-
treotide, administered by subcutaneous (sc) injection,
has been studied extensively since the early 1980s. It is
generally administered in 3 to 4 divided doses of 100–
300 µg per day. The dosage may be initiated at 50 µg/day
in order for patients to adapt to adverse gastrointestinal
effects and titrated upward to achieve the desired effect
[89].
In a series of 35 studies conducted between 1985 and
1995, 978 patients received octreotide sc at dose levels
between 100 µg and 1500 µg/day [55,90–123]. Of these
patients, 54% achieved plasma GH < 5 µg/mL, and 54%
achieved normalized IGF-I. Doses greater than 100 µg
t.i.d. (300 µg/day) seldom resulted in any additional ben-
efit [96,119]. Although some patients have responded fa-
vorably to doses as high as 800 µg/day, the frequency of
octreotide dosing may be more important than the total
daily dose [104].
A slow-release dosage form, octreotide LAR, has
been developed which reduces the need for fre-
quent daily administration while maintaining all of
the clinical and pharmacological characteristics of the
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immediate-release formulation. Clinically, it is typically
given as a once monthly injection. Octreotide LAR, ad-
ministered by intragluteal injection at 1- to 6-week inter-
vals at doses of 10–40 mg, was administered in 303 pa-
tients in a series of 9 studies conducted since 1995 [124–
132]. About 63% of patients achieved GH < 2.5 µg/L and
66% achieved normal IGF-I. Tumor reduction of more
than 20% following octreotide therapy was recorded in
100% of previously untreated patients (n= 4), and 62% of
patients (n = 42) previously treated with medical ther-
apy or surgery had a reduction of tumor size between
20% and 100% [125,126]. It should be noted, however,
that in nearly all of these studies that report efficacy, the
patients had been treated with short-acting octreotide
and had been shown to respond with lowering of GH
before they were treated with the long-acting formula-
tion. Thus, inherent somatostatin nonresponders were
excluded from participating in the long-acting proto-
cols, thereby artificially inflating the efficacy of these
preparations.
The most common side effects of octreotide therapy
are gastrointestinal, specifically nausea and abdominal
pain, which generally appear at the onset of therapy
and decrease in frequency over time [124]. The inci-
dence of diarrhea appears to be dose-related [124]. Ra-
diographically demonstrated gallbladder abnormalities,
especially stones and/or biliary sludge, develop in 18%
of patients on chronic octreotide therapy [124].
III. New Therapeutic Opportunities
in the Management of Acromegaly
Major advances have been made over the last 30 years
in our ability to treat acromegaly, namely, improvement
in surgical results and the development of dopamine
agonists and short- and long-acting forms of the so-
matostain analog, octreotide. Several other novel ther-
apies for acromegaly are under development, and are
as yet not approved by the Food and Drug Adminis-
tration (FDA) or are not well recognized in the litera-
ture. These include short- and long-acting forms of a
relatively new somatostatin analog, lanreotide, the new




Lanreotide, a somatostatin analog, has been used for
7 years in the treatment of acromegaly and is clinically
available in several European countries but has not yet
been approved for use in the United States. It is struc-
turally similar to somatostatin but has better affinity for
the specific somatostatin receptors considered to be re-
sponsible for GH inhibition and, like octreotide, has a
longer duration of action. The shorter-acting form of
lanreotide is provided as a sustained-release micropar-
ticle formulation and has a duration of action of several
weeks [133]. For optimal efficacy, it must be adminis-
tered by intramuscular injection at a dose of 30 mg at
intervals ranging from every 7 to 14 days [134]. How-
ever, optimal drug intervals may be as much as 21 to
28 days due to the marked variability in individual pa-
tient responses [135]. In contrast, the longer-acting form
of lanreotide (Autogel) is administered by deep subcu-
taneous injection in an aqueous base every 28 days at a
dose of 60 to 120 mg, and, therefore, may improve the ac-
ceptability of treatment for patients requiring long-term
therapy [136]. Adverse reactions related to lanreotide
treatment (either formulation) are predominantly gas-
trointestinal and most commonly include diarrhea, ab-
dominal pain, and nausea. These effects are generally
mild and transient. The most potentially important side
effect is the tendency for reduced gall bladder motility,
hence increased incidences of gallstones and sludge in
5 to 10% of patients during prolonged treatment. There-
fore, periodic gall bladder echography evaluations are
recommended. If gallstones do occur, they are gener-
ally asymptomatic. Other common side effects include
constipation and flatulence.
In a multicenter study conducted in Europe [137],
23 patients previously treated with lanreotide 30 mg
every 14, 10, or 7 days for at least 3 months then re-
ceived 60 mg, 90 mg, and 120 mg of lanreotide Auto-
gel, respectively. After 4 months of treatment with the
Autogel formulation, the dose was adjusted as neces-
sary (minimum 60 mg, maximum 120 mg) according
to GH levels (increased if GH > 2.5 µg/mL, decreased
if GH < 1 µg/mL). Before changing to lanreotide Auto-
gel, 39% of patients had a GH level < 2.5 µg/mL and 30%
had a normal age-adjusted IGF-I, which improved af-
ter 8 months of treatment with lanreotide Autogel to
52% and 61% of patients, respectively. No differences in
gall bladder status or in incidence of side effects were
observed. In another multicenter European study, 107
patients were changed from short-acting lanreotide to a
comparable dose of long-acting Autogel for 3 months
[138]. The once-a-month formulation reduced serum
GH to < 2.5 µg/mL in 56% of patients, normalized IGF-
I in 48%, and reduced both GH and IGF-I in 39%. It
was shown to be at least as effective in controlling
GH hypersecretion as intramuscular injections of lan-
reotide 30 mg every 7 to 14 days (Fig. 2). Clinical symp-
toms of acromegaly—headaches, night sweats, asthe-
nia, swelling of extremities, and joint pain—occurred
in 21 to 38% of patients treated with lanreotide Autogel
but, with the exception of headache, there was an im-
provement in each symptom compared to intramuscular
lanreotide (Fig. 3). Diarrhea, abdominal pain, and nau-
sea occurred less frequently in Autogel-treated patients
than in patients treated with lanreotide 30 mg (29%, 17%,
and 9% vs. 38%, 22%, and 18%, respectively.)
III.B. Growth hormone receptor
antagonist, pegvisomant
Pegvisomant is a novel, genetically engineered ana-
log of human GH which functions as a highly selec-
tive GH receptor antagonist. In contrast to existing
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Fig. 2. Lanreotide 30 mg vs. Lanreotide Autogel—biochemical
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Lanreotide 30 mg Lanreotide Autogel
Fig. 3. Lanreotide 30 mg vs. Lanreotide Autogel—symptom
improvement in 107 patients.
medical treatments which inhibit GH secretion, pegvi-
somant specifically inhibits the action of GH [139,140].
In effect, it prevents generation of IGF-I at the cellu-
lar receptor level by binding to GH receptors and in-
terfering with growth hormone receptor mediated sig-
nal transduction [141] (Fig. 4). The targeted effect is
to lower IGF-I; therefore, serum GH is not lowered. Un-
like somatostatin analogs, which require the presence of
subtype-specific somatostatin receptors on the tumor to
Fig. 4. Pegvisomant’s rational design. GHRA, growth hormone
receptor antagonist; hGH, human growth hormone.
inhibit GH secretion (lacking in an estimated 10 to 15%
of patients with acromegaly), the action of pegvisomant
is independent of tumor receptor status [142,143]. Treat-
ment of acromegaly with pegvisomant is by daily subcu-
taneous injection that is self-administered, and the dose
can be titrated to between 10 and 30 mg/day to reach
optimal effect (i.e., decreased IGF-I concentrations).
In a 12-week, double blind, multicenter study, 112 pa-
tients were randomized to receive either placebo or 1 of
3 doses of pegvisomant [144]. A significant decrease in
mean serum IGF-I levels compared with baseline was ev-
ident in all groups within the first 2 weeks of therapy and
was subsequently maintained thereafter until the end of
the study. After 12 weeks of therapy, patients taking 10,
15, or 20 mg of pegvisomant had significant decreases
in mean serum IGF-I levels compared to placebo of 27%,
50%, and 63%, respectively. Furthermore, IGF-I became
normal in 54 to 89% of patients in a dose-related fashion
(Fig. 5). A rise in GH levels, inversely correlated with
the fall in IGF-I, was observed; however, the rise in GH
was not accompanied by an increase in tumor volume.
Treatment with either 15 or 20 mg/day of pegvisoment
resulted in significant reductions in ring size and signifi-
cant improvements in clinical symptoms of acromegaly,
specifically energy level, sweating, and self-perceived
soft tissue swelling. In the continuation of that study,
87 of 90 patients (97%) treated with pegvisomant for
12 to 18 months were found to have a sustained reduc-
tion from their initial IGF-I to the normal age-related
IGF-I range [145]. Improvements in ring size and symp-
toms were also sustained. There was no evidence of
tachyphylaxis.
Side effects of pegvisomant were similar to those re-
ceiving placebo, the most common of which were mild,
self-limited injection site reactions and non-serious up-
per respiratory tract infections. Two patients developed
transaminase elevations requiring withdrawal from ther-
apy; in one case the effect was reversible with a return
to normal transaminase levels upon cessation of the
drug and the other patient was treated for autoimmune
hepatitis. Two patients required treatment for progres-
sion in tumor size. Both had recent transsphenoidal
surgery, and neither had received radiation. Patients
Fig. 5. Percent of patients achieving normal IGF-I
concentrations in a 12-week study of pegvisomant.
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who had been previously treated with radiation very
rarely had an increase in the volume of their tumor while
on pegvisomant therapy. Overall, there was no associ-
ation between the duration of pegvisomant treatment
and change in tumor volume irrespective of the patients’
previous history of radiation therapy [146]. In contrast
to other therapies for acromegaly, in which treatment
outcome is inversely related to the initial concentration
of the serum GH and IGF-I, this medication has proven
effective in nearly all patients treated thus far.
III.C. Gamma Knife radiosurgery
Stereotactic radiotherapy for pituitary tumors using
Leksell’s Gamma Knife technique utilizes multiple
beams of ionizing radiation from a Cobalt-60 source fo-
cused on the tumor [146]. With increased precision and
accuracy, further enhanced by the use of MRI for radi-
ological localization of the lesions [28], a high dose of
radiation can be delivered in a single session while min-
imizing the risk of serious complications, specifically,
damage to nearby optic pathways. In contrast, conven-
tional radiotherapy of pituitary tumors is generally deliv-
ered in fractionated doses of 160–180 cGy 4–5 times per
week over a 5- to 6-week period (45–50 Gy) [28]. Gamma
Knife radiosurgery has been primarily employed in cases
of incomplete surgical removal to treat recurrent tumors
or small remnants of tumor that are at least 5 mm away
from the optic chiasm. Dosing plans are determined by
tumor size, the relationship of the tumor to adjacent
critical structures, and past history of radiotherapy, and
utilize multiple shots to deliver 50% of the maximum
dose of radiation to the periphery of the tumor [28].
Marginal doses of between 20 and 35 Gy and maximum
doses between 40–70 Gy have been reported for control
of secreting adenomas [147].
Although stereotactic Gamma Knife radiosurgery has
been used since 1973, data regarding the effectiveness
of this form of therapy are meager. Few studies have em-
ployed the modern criteria for the cure of acromegaly,
i.e., GH < 2.5 µg/L and a normal age-adjusted IGF-I. In
a series of 11 studies in which IGF-I was the measure
of efficacy, a review of 256 patients followed for at least
6 months after undergoing Gamma Knife radisurgery
showed that 35% of patients achieved normalized IGF-I,
an efficacy rate nearly identical to that of conventional
radiation [28,34,35,38,148–154]. Using the strictest crite-
ria for the cure of acromegaly (normal age-adjusted IGF-
I and GH < 1 µg/L), Vance and colleagues have treated
85 patients with acromegaly not cured by surgery; 58
patients were evaluable (Vance ML, personal commu-
nication). In this as yet unpublished study, patients un-
derwent Gamma Knife radiosurgery followed by medi-
cal therapy, including octreotide and lanreotide. Medical
therapy was stopped every 6 months for an evaluation.
At a mean of 27 months (range, 5–98 months), 17 of 58
(29%) evaluable patients had IGF-I that was normal for
age. New onset hypopituitarism occurred in 29%.
With Gamma Knife radiosurgery, resolution of pitu-
itary hypersecretion begins earlier than with conven-
tional radiotherapy. In a study comparing conventional
fractionated radiotherapy with stereotactic Gamma
Knife radiosurgery in patients with acromegaly, the ben-
eficial effects of Gamma Knife on excess GH and IGF-
I occurred much earlier than fractionated radiation;
the mean time to simultaneous normalization of both
GH and IGF-I was 1.4 years in patients treated with
Gamma Knife radiation and 7.1 years in those treated
with fractionated radiation [155].
Early studies suggest that the side effects associated
with the use of Gamma Knife technique are similar to
that of conventional radiation but occur less frequently.
Other benefits may be found in the use of focused ra-
diosurgery for additional radiation effect following con-
ventional radiation depending on the doses previously
given and the proximity of the lesion to the optic chi-
asm. Further long-term study, however, is needed to de-
termine the safety and effectiveness of Gamma Knife
radiosurgery and other radiosurgical techniques as a
treatment for acromegaly.
IV. Conclusions
The primary goals in the treatment of acromegaly are
to alleviate tumor mass effects and normalize IGF-I
in order to ultimately reduce the morbidity and mor-
tality rates. Although surgery remains the initial treat-
ment in most cases, adjunctive treatment with medical
therapy and/or radiation is often necessary for opti-
mal treatment, as a significant proportion of patients
continue to have elevated IGF-I levels following any
given treatment. With the improved delivery and effi-
cacy of longer-acting dopamine agonists and somato-
statin analogs, and the advent of a novel new class of GH
receptor antagonist drugs such as pegvisomant, promis-
ing new therapeutic opportunities exist in the manage-
ment of acromegaly. The use of radiation continues to
be justified in patients whose tumors are unresponsive
to medical therapy and may perhaps allow for eventual
termination of medical therapy in some patients. How
newer therapies will affect our treatment approaches to
patients with acromegaly still remains to be determined.
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